EC Number   |
Application |
Reference |
|---|
   2.3.1.B43 | diagnostics |
elevated SIRT5 expression in human breast tumors correlates with poor patient prognosis |
758247 |
| 2.3.1.B43 | drug development |
SIRT5 is a drug target |
756522 |
| 2.3.1.B43 | drug development |
Sirt5 is a potential drug target for the treatment of cancer, Alzheimer's disease, and Parkinson's disease |
757350 |
| 2.3.1.B43 | medicine |
pharmacological interventions on SIRT5 expression may be useful in the treatment of oxidative stress-related cardiac injury |
729556 |
| 2.3.1.B43 | medicine |
SIRT5 is involved in influencing oocyte quality and in-vitro-fertilisation outcomes |
730922 |
| 2.3.1.B43 | medicine |
SIRT5 may have therapeutic value to treat hyperammonemia |
728932 |
| 2.3.1.B43 | medicine |
SIRT5 may serve as a potential prognostic factor and drug target for intervention in non-small cell lung cancer. SIRT5 is overexpressed in human non-small cell lung cancer cells, high expression of SIRT5 predicts poor survival. SIRT5 knockdown makes lung cancer cells more sensitive to drug (cis-diamminedichloroplatinum, 5-fluorouracil or bleomycin) treatment in vitro and in vivo. Nrf2, which is a core transcription factor for lung cancer growth and drug resistance, is a target of SIRT5 |
731010 |
